GPC3/CD3 Bispecific Antibodies for Selective T-Cell Tumor Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for GPC3-positive tumors, including bispecific antibodies and CAR T-cell therapies, have limitations in efficacy and specificity, failing to adequately target and kill tumor cells while minimizing toxicity.
Innovation Solution
Development of GPC3-specific antibodies and chimeric antigen receptors (CARs) with high binding affinity and reduced cytotoxicity, combined with GPC3/CD3 bispecific antibodies to enhance T-cell targeting and signaling, and CAR-T cells for targeted tumor cell killing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current bisspecific antibodies and CAR T-cell therapies are used for GPC3-positive tumors, then T-cell targeting is achieved, but efficacy and specificity are insufficient leading to inadequate tumor cell killing and excessive toxicity
Solution Approach 1:
The patent applies local quality by designing antibodies with differential affinity characteristics - the GPC3-binding domain exhibits high affinity and specificity for tumor cells, while the CD3-binding domain is engineered with controlled affinity to activate T cells effectively. This localized optimization of binding properties at different interaction sites enables selective tumor targeting while minimizing off-target toxicity to healthy tissues
Solution Approach 2:
The patent employs parameter changes by systematically optimizing key parameters including antibody affinity constants, half-life characteristics, and molecular weight through engineering modifications. The GPC3/CD3 bispecific antibody parameters are tuned to achieve optimal T-cell activation thresholds and tumor cell binding strength, thereby improving killing efficacy while reducing excessive immune activation that causes toxicity
2Reliability
If current treatments are used, then some tumor targeting is achieved, but specificity is insufficient leading to off-target effects
Solution Approach 1:
The patent applies local quality by designing antibodies with differential affinity characteristics - the GPC3-binding domain exhibits high affinity and specificity for tumor cells, while the CD3-binding domain is engineered with controlled affinity to activate T cells effectively. This localized optimization of binding properties at different interaction sites enables selective tumor targeting while minimizing off-target toxicity to healthy tissues
Solution Approach 2:
The patent uses T cells as an intermediary element - the bispecific antibody does not directly kill tumor cells but rather recruits and activates endogenous T cells to perform the cytotoxic function. This intermediary mechanism enhances specificity because T cells naturally recognize tumor antigens through their TCRs, adding a layer of biological selectivity that reduces off-target effects compared to direct antibody-mediated cytotoxicity
3Power
If GPC3/CD3 bispecific antibodies are developed with high binding affinity, then T-cell activation is enhanced, but cytotoxicity may increase
Solution Approach 1:
The patent applies partial action by engineering the CD3-binding domain with affinity parameters optimized for sufficient T-cell activation without excessive engagement. The antibody provides just enough activation signal to trigger effective T-cell responses against tumor cells, while avoiding over-activation that would lead to excessive cytotoxicity and immune-mediated damage to healthy tissues
Solution Approach 2:
The patent incorporates feedback mechanisms through the natural regulation of T-cell activation - the bispecific antibody triggers T-cell engagement which then modulates its own activity through cytokine release and activation markers. This biological feedback system allows the therapy to self-regulate cytotoxicity levels based on tumor burden and immune system state, preventing uncontrolled toxicity while maintaining effective anti-tumor activity
Data Source
AI summary
Provided herein are novel Glypican 3 (GPC3) antibodies or antigen binding fragments and GPC3/CD3 bispecific antibodies. The present application also provides chimeric antigen receptors comprising the antibodies or antigen-binding fragments, related CAR-T cells, and preparation methods and uses of the same. The present application further provides pharmaceutical compositions comprising GPC3 antibodies or antigen binding fragments, related GPC3/CD3 bispecific antibodies, related GPC3 CAR or CAR-T cells, and methods of treating cancer in a subject in need thereof by administering the Glypican 3 (GPC3) antibodies or antigen binding fragments, the bispecific antibodies, the chimeric antigen receptors, the CAR-T cells, or the pharmaceutical compositions. The cancers treated in accordance with the application include Glypican-3-positive cancers.